Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of bleximenib in acute leukemia, acute myeloid leukemia (AML), sponsored by Janssen Pharmaceutical. Started May 2021; status: recruiting.
02
Drugs
bleximenib
03
Conditions
acute leukemiaacute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04811560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811560.